Arcus Biosciences (RCUS) Tops Q1 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.09), $0.06 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.99 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Retail investors largely unaware of SEC semiannual reporting proposal